top of page
TRASTYVERE
CLINICAL BENEFIT OF THE TREATMENT WITH TRASTUZUMAB IN COMBINATION WITH LAPATINIB IN METASTATIC BREAST CANCER HER2 POSITIVE PATIENTS WHO HAS BEEN PREVIOUSLY TREATED WITH TRASTUZUMAB AND/OR LAPATINIB.
CLINICAL TRIAL DETAILS
OBSERVATIONAL, RETROSPECTIVE AND MULTICENTER STUDY TO EVALUATE THE CLINICAL BENEFIT OF TRASTUZUMAB IN COMBINATION WITH LAPATINIB IN METASTATIC BREAST CANCER HER2 POSITIVE PATIENTS WHO HAS BEEN PREVIOUSLY TREATED WITH TRASTUZUMAB AND/OR LAPATINIB.
A RETROSPECTIVE, OBSERVATIONAL, NOT EPA, MULTICENTER STUDY TO EVALUATE THE CLINICAL BENEFIT OF TRASTUZUMAB IN COMBINATION WITH LAPATINIB IN METASTATIC BREAST CANCER HER2 POSITIVE PATIENTS WHO HAS BEEN PREVIOUSLY TREATED WITH TRASTUZUMAB AND/OR LAPATINIB BETWEEN JANUARY 2005 AND DECEMBER 2011.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
BREAST (Her2-)
14
111
Retrospective
Spain
CLOSING
PRESS RELEASE
-
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
TRIAL SITES
-
bottom of page